Skip to content
Log in
Sponsored AI AM CLAUDE, A Beginner's Guide: Learn the basics of working with AI AI AM CLAUDE, A Beginner's Guide: Learn the basics of working with AI

Author

N. Boku

View on Semantic Scholar

4 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Sep 2026

PD-L1 expression and survival in unresectable/recurrent gastric cancer treated by 1st-line treatment without immune checkpoint inhibitors: JCOG1013A1.

BACKGROUND The prognostic significance of PD-L1 expression in unresectable/recurrent gastric cancer treated by first-line chemotherapy without an immune checkpoint inhibitor (ICI) remains unclear. The phase III trial JCOG1013 demonstrated no overall survival (OS) or progression-free survival (PFS) benefit of docetaxel/...

H. Hirano, Yasuhide Yamada, Kengo Nagashima et al. · 0 citations
Open access Oct 2026

Survival Results by the Prospectively Determined Clinical Staging for Locally Advanced Gastric Cancer: A Follow‐Up Study of JCOG1302A

ABSTRACT Background Long‐term overall survival (OS) of gastric cancer stratified by the prospectively determined clinical stage remains unclear. Methods This is an ancillary study of JCOG1302A, a prospective observational study that evaluated the accuracy of clinical diagnosis of gastric cancer with cT2/T3/T4, cN0/N1/N...

Tsutomu Hayashi, Ryosuke Kato, Noriko Mitome et al. · 0 citations
Oct 2026

Treatment Outcomes for Gastric Cancer With Positive Peritoneal Lavage Cytology or Localized Peritoneal Metastasis.

Importance In the era of modern systemic chemotherapy, the optimal treatment strategy for gastric cancer with positive peritoneal lavage cytology (CY1) and/or localized peritoneal metastasis (P1a) remains controversial. Objective To explore the optimal treatment strategy for patients with gastric cancer with CY1 and/...

Keiichi Fujiya, Masanori Tokunaga, Kazuyoshi Yamamoto et al. · 1 citation
Open access Sep 2026

A multicenter phase II trial of ramucirumab plus irinotecan for early recurrence of gastric cancer during or after adjuvant chemotherapy with docetaxel plus S-1 therapy: the RAMIEL trial (OGSG1901).

BACKGROUND There is currently no established chemotherapy regimen for early recurrence of pathological stage III gastric cancer (GC) following adjuvant chemotherapy with docetaxel plus S-1 (DS) after D2 gastrectomy. We aimed to evaluate the efficacy and safety of ramucirumab plus irinotecan in patients with GC who expe...

Toshifumi Yamaguchi, R. Kawabata, Y. Akamaru et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.